hero section gradient
15 handpicked stocks

Accelerators

Discover companies that are fundamentally changing how businesses operate by providing the essential software and platforms that drive speed, efficiency, and innovation. These carefully selected stocks represent leaders in the digital transformation space, powering the future of enterprise technology.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Concise summary and investor takeaways for the 'Accelerators' basket market capitalisation data.

Key Takeaways for Investors:
  • Large-cap dominance usually means lower volatility and returns that tend to track broader market movements.
  • Treat as a core, diversified holding rather than a speculative, high-growth allocation.
  • Expect steadier, long-term appreciation rather than explosive short-term gains; growth likely moderate.
Total Market Cap
  • NOW: $195.83B

  • SNOW: $83.86B

  • NET: $74.22B

  • Other

About This Group of Stocks

1

Our Expert Thinking

These companies provide the critical infrastructure that enables businesses to operate faster and smarter. From cloud computing and AI-driven automation to rapid data analytics, these technologies are the backbone of modern business efficiency and competitiveness in the digital economy.

2

What You Need to Know

This growth-oriented collection focuses on market leaders whose technologies create significant competitive advantages through speed and scale. As companies globally prioritize digital transformation, these firms become increasingly indispensable, potentially offering long-term growth opportunities.

3

Why These Stocks

We've selected pivotal companies in enterprise software and cloud infrastructure whose solutions drastically reduce time-to-execution across business processes. These firms are strategically positioned to benefit from the ongoing integration of artificial intelligence across all business functions.

Why You'll Want to Watch These Stocks

🚀

Riding the AI Wave

These companies are at the forefront of the artificial intelligence revolution, providing the essential tools businesses need to implement and scale AI solutions quickly.

💼

Essential, Not Optional

In today's fast-paced business environment, these acceleration technologies aren't luxury items—they're mission-critical for companies that want to remain competitive and relevant.

🔄

Never-Ending Demand

Digital transformation isn't a one-time event but a continuous journey, creating persistent demand for these acceleration solutions as businesses constantly adapt and evolve.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions